Viale Europa Cantanzaro, Italy

  • Featured

    Integument-2 study

    The study drug consists of a cream of the medication or a placebo (same cream without the active drug) that will be applied once daily for 28 days. This treatment is experimental, and you (or your child) will have 1 in 2 chances to be part of the placebo part of the study. At the end of the study, participants may be eligible to participate in the open-labeled study, which would allow the participants to continue to receive the study treatment. More information will be made available to the participants should they be interested. Blood samples will be collected on screening, day 1 and week 4. If you consent to medical photography, it will be performed at day 1, week 1 and week 4. For more information and to register to the study, please visit the study page: http://eczema-study.com/

    Phase

    3

    Span

    Sponsor

    Surrey, British Columbia

    Recruiting

  • Featured

    INCB 18424-303: Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE-AD1)

    NCT03745638 For more information, please contact Incyte Corporation at 1.855.463.3463

    Phase

    3

    Span

    Sponsor

    SURREY, British Columbia

    Recruiting

  • Featured

    We are currently recruiting patients with Palmoplantar Pustulosis (PPP). This study investigates the Efficacy and safety of ANB019.

    Visit our website for more information: [_**www.pustulardermstudies.com**_](https://ppp.pustulardermstudies.com/patient/qualify/?media_label=centerwatch)

    Phase

    2

    Span

    Sponsor

    Surrey, British Columbia

    Recruiting

1-3 of 3